Cell Biotech Co

Cell Biotech Co Total Assets

The Total Assets of Cell Biotech Co (049960.KQ) as of Oct 16, 2026 is 136.57 B KRW. In the previous year, Total Assets was 130.40 B KRW — a change of 4.74% (higher).

Total Assets

136.57 BKRW

YoY

4.74%

Last updated:

Total Assets of Cell Biotech Co is 2025 136.57 B KRW. Total Assets of Cell Biotech Co was 2024 130.40 B KRW. It decreases by 4.74% higher compared to the previous year.

The Cell Biotech Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
112.05 B KRW
Jan 1, 2019
108.30 B KRW
Jan 1, 2020
105.30 B KRW
Jan 1, 2021
112.88 B KRW
Jan 1, 2022
115.84 B KRW
Jan 1, 2023
117.64 B KRW
Jan 1, 2024
130.40 B KRW
Jan 1, 2025
136.57 B KRW
The Cell Biotech Co Total Assets history
YEARTotal AssetsYoY
136.57 BKRW+4.74%
130.40 BKRW+10.84%
117.64 BKRW+1.56%
115.84 BKRW+2.62%
112.88 BKRW+7.19%
105.30 BKRW-2.77%
108.30 BKRW-3.34%
112.05 BKRW+16.14%
96.48 BKRW+6.57%
90.53 BKRW+20.76%
74.97 BKRW+30.14%
57.60 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co Ltd is a South Korean company based in Gimpo, Gyeonggi-Do, operating within the Health Care sector, specifically in the Biotechnology industry. The company went public through an IPO on December 13, 2002. Its primary focus is on the research, development, and manufacturing of probiotics, particularly lactobacillus-based products. Cell Biotech produces lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines aimed at enhancing immunity and improving digestion. Additionally, the company develops finished products containing LABs, designed for applications such as intestinal health improvement, carcinogen inhibition, and calcium supplementation. These products are distributed both domestically within South Korea and internationally. The company's website is http://www.cellbiotech.com/, providing further information about its operations and offerings. Cell Biotech's activities are centered around biotechnology solutions that support health and wellness through probiotic applications. The firm operates with a focus on research and development to advance its product lines, though specific details about its research initiatives or product names beyond the mentioned categories are not provided. The company's market presence spans both domestic and international channels, reflecting its commitment to delivering probiotic-based health solutions across various markets. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Total Assets of Cell Biotech Co is 136.57 B KRW in 2025.

Total Assets of Cell Biotech Co changed from 130.40 B KRW to 136.57 B KRW, representing a 4.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cell Biotech Co

All Key Metrics — Cell Biotech Co